Factors Influencing Implementation of the Survivorship Passport: The IT Perspective.

Cancer Survivors Childhood Cancer Electronic Medical Records HL7 FHIR International Patient Summary Paediatric Oncology Survivorship Passport

Journal

Studies in health technology and informatics
ISSN: 1879-8365
Titre abrégé: Stud Health Technol Inform
Pays: Netherlands
ID NLM: 9214582

Informations de publication

Date de publication:
16 05 2022
Historique:
entrez: 20 5 2022
pubmed: 21 5 2022
medline: 24 5 2022
Statut: ppublish

Résumé

Compared to the general population, childhood cancer survivors represent a vulnerable population as they are at increased risk of developing health problems, known as late effects, resulting in excess morbidity and mortality. The Survivorship Passport aims to capture key health data about the survivors and their treatment, as well as personalized recommendations and a care plan with the aim to support long-term survivorship care. The PanCareSurPass (PCSP) project building on the experience gained in an earlier implementation in Giannina Gaslini Institute, Italy, will implement and rigorously assess an integrated, HL7 FHIR based, implementation of the Survivorship Passport. The six implementation countries, namely Austria, Belgium, Germany, Italy, Lithuania, and Spain, are supported by different national or regional digital health infrastructures and Electronic Medical Record (EMR) systems. Semi structured interviews were carried out to explore potential factors affecting implementation, identify use cases, and coded data that can be semi-automatically transferred from the EMR to SurPass. This paper reflects on findings of these interviews and confirms the need for a multidisciplinary and multi-professional approach towards a sustainable and integrated large-scale implementation of the Survivorship Passport across Europe.

Identifiants

pubmed: 35592976
pii: SHTI220363
doi: 10.3233/SHTI220363
doi:

Types de publication

Journal Article

Langues

eng

Pagination

161-168

Auteurs

Catherine Chronaki (C)

HL7 Europe, Brussels, Belgium.

Eliana Charalambous (E)

HL7 Europe, Brussels, Belgium.
Venizeleio General Hospital of Heraklion, Heraklion, Greece.

Giorgio Cangioli (G)

HL7 Europe, Brussels, Belgium.

Günter Schreier (G)

AIT Austrian Institute of Technology, Graz, Austria.

Selina van den Oever (S)

Princess Maxima Center for Paediatric Oncology, Utrecht, The Netherland.

Helena van der Pal (H)

Princess Maxima Center for Paediatric Oncology, Utrecht, The Netherland.

Leontien Kremer (L)

Princess Maxima Center for Paediatric Oncology, Utrecht, The Netherland.

Anne Uyttebroeck (A)

University Hospitals Leuven, Leuven, Belgium.

Bart Van den Bosch (B)

University Hospitals Leuven, Leuven, Belgium.

Justas Trinkunas (J)

Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.

Jelena Rascon (J)

Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.

Ruth Ladenstein (R)

Children's Cancer Research Institute, Vienna, Austria.
St. Anna Children's Hospital, Vienna, Austria.

Vanessa Düster (V)

Children's Cancer Research Institute, Vienna, Austria.

Edit Bardi (E)

St. Anna Children's Hospital, Vienna, Austria.
Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria.

Diana Walz (D)

Division Medical Documentation, IMBEI, University Medical Center Mainz, Mainz, Germany.

Anna-Liesa Filbert (AL)

German Childhood Cancer Registry, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

Desiree Grabow (D)

German Childhood Cancer Registry, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

Thorsten Langer (T)

University of Lübeck, Lübeck, Germany.

Adela Cañete Nieto (A)

Fundacion para la Investigacion del Hospital Universitario La Fe De La Comunidad Valenciana, Valencia, Spain.

Antonio J Orduña Galán (AJ)

Fundacion para la Investigacion del Hospital Universitario La Fe De La Comunidad Valenciana, Valencia, Spain.

Marisa Correcher Palau (M)

Fundacion para la Investigacion del Hospital Universitario La Fe De La Comunidad Valenciana, Valencia, Spain.

Giacomo Cavalca (G)

IRCCS, Istituto Giannina Gaslini, Genova, Italy.

Riccardo Haupt (R)

IRCCS, Istituto Giannina Gaslini, Genova, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH